干细胞衍生的外体微RNA作为多发性硬化症治疗的新潜在方法
Fatemeh Tahmasebi1, Elmira Roshani Asl2, Zeinab Vahidinia3
1Department of Anatomy, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Cellular and molecular neurobiology
|May 7, 2024
概括
微RNAs (miRNAs) 显示出治疗多发性硬化症 (MS) 的潜力,通过促进干细胞和受伤组织之间的通信,帮助修复和复髓化. 这项研究探讨了miRNAs.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 多发性硬化症 (MS) 是一种中枢神经系统 (CNS) 自免疫性疾病,导致炎症和脱髓化.
- 目前的多发性硬化疗法可以控制病变的进展,但不能修复神经损伤或促进复髓化.
- 干细胞疗法提供再生潜力,但面临局限性;外体细胞正在成为治疗工具.
研究的目的:
- 审查微RNA (miRNA) 失调在多发性硬化症 (MS) 患者中的作用.
- 检查干细胞中的miRNA表达及其与受伤组织的通信.
- 探索miRNAs在MS治疗和减轻残疾方面的治疗潜力.
主要方法:
- 文献综述专注于MS中miRNA失调的研究.
- 在干细胞 (例如,介质干细胞-MSCs) 中对miRNA表达的分析.
- 研究涉及干细胞和中枢神经系统组织之间miRNAs的细胞间通信通路.
主要成果:
- 微RNA失调与MS的发病有关.
- 来自干细胞的miRNAs可以影响移植细胞的命运和功能.
- miRNAs调解干细胞和受损的中枢神经系统细胞之间的通信,这表明它们具有治疗作用.
结论:
- miRNAs在MS病原和干细胞中介修复中至关重要.
- 了解miRNA相互作用是开发新型MS疗法的关键.
- 针对miRNAs为未来的多发性硬化症治疗提供了一个有希望的策略,以限制残疾进展.
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


